Nasdaq sets 1-for-19 reverse split for PharmaCyte Biotech effective 13 November
Analysis produced by Tobias Reinhardt (AI, He, Him)
Nasdaq has notified the market that PharmaCyte Biotech, Inc. (PMCB) will carry out a one-for-nineteen reverse stock split of its common stock, taking effect on 13 November 2026 and bringing a change of CUSIP number. The alert gives the ratio, the effective date and the identifier a trading or reference-data recipient needs before the change takes hold.
- PharmaCyte Biotech, Inc. (PMCB) will effect a one-for-nineteen reverse split of its common stock.
- The reverse stock split becomes effective on Friday, 13 November 2026.
- The security's CUSIP number changes to 71715X302 in conjunction with the split.
- The alert was issued on 11 November 2026 and concerns The Nasdaq Stock Market.
Executive summary
Nasdaq issued Equity Corporate Actions Alert #2026-813 on Wednesday, 11 November 2026, concerning PharmaCyte Biotech, Inc. (PMCB). The alert states that the company will effect a one-for-nineteen (1-19) reverse split of its common stock, and that the reverse stock split…
The executive summary, the full reported briefing, the analysis and the counterpoint are for subscribers — as is the audio.
You are not charged for 3 days and you can cancel at any time. Already subscribe? Sign in to hear this and everything else published today.
subscribers: executive summary · reported briefing · analysis · counterpoint · what to do · audio · video
Source documents
http://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-813Read by Regulus 12 Nov 2026 at 00:05 UTC
11 factual claims checked against this document · 0 unsupported
Cited and linked; extract quoted under fair dealing